

Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD)

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (20 December 2024) granted a conditional marketing authorisation for the medicine givinostat (Duvyzat) to treat Duchenne muscular dystrophy (DMD).